California medical device maker Volcano manages releases record preliminary 4th-quarter revenues, touting its leadership position at this year's J.P. Morgan healthcare conference.
If it hits that target, Volcano's full-year sales will amount to nearly $392 million, a jump of about 10% over 2011.
Sales were partly driven by a 42% increase in disposable fractional flow reserve products, a segment expected to be worth about $27.2 million in sales during the 3 months ended December 31.
Volcano develops products in a self-defined region it calls "precision-guided therapy," meaning a combination of imaging and therapeutic systems that are integrated into a single platform.
"We're really the only pure-play in this segment," president & CEO Scott Huennekens told an audience today in San Francisco. "This year, 2013, is going to be the 1st year that this market segment is over $1 billion in revenue by our projections and outside consultants, analysts, et cetera."
Volcano has put its money on integrated imaging and therapeutics systems and disposables for those systems, where Huennekens said the company has a "winning strategy."
Will the $66 billion buyout of Allergan by Actavis suck some of the juice out of Orange County, Calif...
Johnson & Johnson wants a federal judge to make Boston Scientific cough up some $7.2 billion - 40...
Boston Scientific goes down in another product liability lawsuit over its pelvic mesh products.
What's a medical device company to do when Facebook and Twitter can spread word of its products...